Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus for brain MRI abnormalities in tuberous sclerosis complex
IRCT20180928041159N2Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of everolimus in tuberous sclerosis complex (TSC) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Volume changes in giant astrocytoma and Decrease in the volume of subependymal nodules. Started Jan 2020; status: completed.
02
Drugs
everolimus
03
Conditions
tuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on IRCT20180928041159N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180928041159N2.